Welcome to our dedicated page for Sera Prognostics news (Ticker: SERA), a resource for investors and traders seeking the latest updates and insights on Sera Prognostics stock.
Sera Prognostics, Inc. (SERA) delivers innovative diagnostic solutions for pregnancy complications through advanced biomarker technology. This news hub provides investors and healthcare professionals with essential updates on clinical developments, strategic partnerships, and regulatory milestones shaping maternal health diagnostics.
Access authoritative reporting on SERA's progress in precision medicine, including trial results for preterm birth prediction tests and collaborations with leading research institutions. Our curated news collection simplifies tracking of material events influencing the company's position in the $50B+ prenatal diagnostics market.
Key updates include FDA submissions for novel tests, peer-reviewed study publications, and commercial expansion initiatives. All content undergoes rigorous fact-checking to ensure compliance with financial disclosure standards while maintaining clinical accuracy.
Bookmark this page for real-time alerts on earnings announcements, intellectual property developments, and leadership changes. Stay informed about SERA's contributions to reducing neonatal complications through early intervention strategies validated by clinical evidence.
Sera Prognostics Inc. (Nasdaq: SERA) announced the rescheduling of its presentation at the virtual Citi 2022 Healthcare Conference, now set for February 24, 2022, at 9:30 a.m. EST. CEO Gregory C. Critchfield will provide an update and discuss recent achievements. A live webcast will be available on Sera's website, although no replay will be offered. Sera Prognostics is dedicated to enhancing maternal and neonatal health, focusing on early prediction of preterm birth risks through its PreTRM® Test, aimed at enabling proactive interventions.
Sera Prognostics, the Pregnancy Company® (Nasdaq: SERA), announced its participation in two upcoming virtual investor conferences: the BTIG MedTech Conference on February 17, 2022, and the Citi 2022 Healthcare Conference on February 24, 2022. CEO Gregory C. Critchfield will provide updates on the company's innovative pregnancy biomarker solutions. Sera's PreTRM® Test offers individualized risk predictions for preterm birth. Notably, 10% of infants are born prematurely in the U.S., incurring healthcare costs of approximately $25 billion annually.
Sera Prognostics Inc. (NASDAQ: SERA) announced a new agreement with MultiPlan to enhance access to its PreTRM® Test, a blood-based biomarker test predicting the risk of preterm birth. This partnership will allow for better medical intervention through MultiPlan's extensive network of over 700 healthcare payers and 1.2 million providers. The PreTRM® Test is crucial for identifying high-risk pregnancies early, enabling personalized care plans. Sera aims to broaden adoption of this test, which is pivotal for improving maternal and neonatal health while reducing healthcare costs.
Sera Prognostics, known as The Pregnancy Company, will be added to the NASDAQ Biotechnology Index effective December 20, 2021. This inclusion underscores Sera's commitment to enhancing maternal and neonatal health through innovative pregnancy biomarker information. The Nasdaq Biotechnology Index tracks securities in the biotech and pharmaceutical sectors, requiring companies to meet stringent criteria such as market capitalization and trading volume. Sera's PreTRM® test provides early risk assessments for preterm birth, which affects over 10% of U.S. births annually.
Sera Prognostics Inc. (NASDAQ: SERA) announced that the Centers for Medicare & Medicaid Services (CMS) has established a Medicare payment rate of $750.00 for the PreTRM® test under the Proprietary Laboratory Analysis code 0247U. This rate will take effect on January 1, 2022, and applies for CY 2022. While this pricing reinforces the test's value, Medicare coverage is not guaranteed. The company aims to negotiate broader insurance coverage to enhance patient access to this innovative test, which predicts the risk of spontaneous preterm birth.
Sera Prognostics (NASDAQ: SERA), focused on maternal and neonatal health, announced the publication of a study funded by the Bill & Melinda Gates Foundation in partnership with AMANHI. This study validates the predictive performance of the IBP4/SHBG biomarker pair for spontaneous preterm birth (sPTB) in low and middle-income regions. Conducted on 10,001 pregnant women in Bangladesh, Pakistan, and Tanzania, results confirm that the biomarkers predict sPTB effectively, enhancing the potential for broader application outside of the U.S.
Sera Prognostics Inc. (NASDAQ: SERA) announced the appointment of Sandra A. J. Lawrence to its Board of Directors. Ms. Lawrence brings extensive leadership experience and insights from her roles in public and private boards, as well as her tenure as CFO at Children’s Mercy Hospital. The company aims to leverage her expertise to enhance maternal and neonatal health and drive long-term revenue growth. Sera Prognostics specializes in innovative pregnancy biomarker solutions, particularly its PreTRM® test, which aims to predict preterm birth risks.
Sera Prognostics Inc. (Nasdaq: SERA) reported a significant revenue increase for Q3 2021, achieving $23,000 compared to $5,000 in Q3 2020. Operating expenses rose to $9.5 million from $4.6 million, primarily due to expanded sales operations and public company costs. R&D spending increased to $2.7 million, reflecting heightened clinical study efforts. The company faced a net loss of $9.9 million, up from $5.1 million year-over-year. Sera continues to see early payer revenues for its PreTRM® test, emphasizing its commitment to improving maternal and neonatal health.
Sera Prognostics, Inc. (NASDAQ: SERA) announced the appointment of Zhenya Lindgardt to its Board of Directors, effective immediately. Lindgardt, with extensive experience in healthcare and technology, aims to enhance the company's mission to improve maternal and neonatal health. Currently the CEO of The Commons Project Foundation, she has also held significant positions at Uber Technologies and The Boston Consulting Group. CEO Gregory C. Critchfield expressed enthusiasm about Lindgardt’s contributions towards innovative solutions for pregnancy-related challenges.
Sera Prognostics (NASDAQ: SERA) has appointed Woodrow Myers, M.D., M.B.A., as an advisor for public and political affairs. Dr. Myers will spearhead initiatives addressing health equity and disparities during pregnancy, a significant focus for the company. Gregory C. Critchfield, CEO, emphasized Dr. Myers' leadership experience in healthcare management and quality initiatives. Sera Prognostics aims to enhance maternal and neonatal health through innovative diagnostic tests like the PreTRM®, which predicts preterm birth risk, thereby enabling timely interventions.